1 / 24

Large sample dose content uniformity test: parametric and nonparametric (counting)

Large sample dose content uniformity test: parametric and nonparametric (counting). Meiyu Shen, PhD Collaborators: Xiaoyu Dong, Ph.D., Yi Tsong, PhD Office of Biostatistics, CDER, FDA

jameys
Download Presentation

Large sample dose content uniformity test: parametric and nonparametric (counting)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Large sample dose content uniformity test: parametric and nonparametric (counting) Meiyu Shen, PhD Collaborators: Xiaoyu Dong, Ph.D., Yi Tsong, PhD Office of Biostatistics, CDER, FDA * This presentation contains opinions of the authors that do not represent the official position of U.S. Food and Drug Administration

  2. Outline • Purpose of uniformity of dosage unit • Harmonized USP dose content uniformity test with a small sample • Large n dose content uniformity test • EU methods • Option 1: Parametric method • Option 2: Nonparametric method (Counting method) • Two one-sided tolerance interval method • Comparison between the EU method and the two one-sided tolerance interval method • Conclusion

  3. Uniformity of dosage unit • The purpose of uniformity of dosage unit • The degree of uniformity in the amount of the drug substance among dosage units. • Demonstrated by one of the follows • Dose content uniformity (focus here) • based on the assay of the individual content of drug substance(s) in a number of dosage units • Weight variation

  4. Indifferent zone • M:

  5. Harmonized USP DCU for small n Step 1, 10 tablets Step 2, additional 20 tablets No Yes Fail Yes Pass Pass

  6. EU option 1 for large n≥100 Take n tablets, {Xi}, i=1,2,…,n No Fail Yes 6 Pass

  7. EU option 2 for large n≥100 Take n tablets, {Xi}, i=1,2,…,n No Fail Yes Pass 7

  8. EU Option 2 acceptable number of individual units c1 outside (1±0.15) and c2 outsides (1±0.25)

  9. PTIT_matchUSP90 Take n tablets, {Xi}, i=1,2,…,n No Fail Yes Pass 9

  10. EU option 1 and PTIT_matchUSP90 EU Option 1 PTIT_matchUSP90 Two one-sided tolerance interval Control probability each tail outside (85,115)% Two one-sided hypothesis • Two-sided tolerance interval • Control probability within (85,115)% • Two-sided hypothesis P (1-P)/2

  11. EU option 1 and PTIT_matchUSP90 EU Option 1 PTIT_matchUSP90 Formula for K Confidence level: 1-α=0.95 Each tail probability: (1-p(n))/2 For n=30, p=82.04%, • Formula for K • Confidence level: • Center Coverage:

  12. K values of EU Option 1 and PTIT_matchUSP90

  13. Normal: on target product, mean=100%

  14. Normal: off target product, mean=102%

  15. Mixed normal: on target overall mean

  16. Mixed normal: off target overall mean

  17. Bias of EU Option 1

  18. Special distribution • Assume the individual tablet dose content is distributed as a uniform distribution in the range from 85% to 115% with 97% probability and a value 84% with 3% probability. • The probability of passing USP harmonized DCU is 3.72% for a sample size of 30 tablets. • Comparison of EU Option 2 and PTIT_matchUSP90 in next table • EU Option 2 has 45.5% probability to pass the DCU test when n=300. • the PTIT_macthUSP90 has zero passing probability for n≥100.

  19. EU Option 2 and PTIT_matchUSP90 Xi: a uniform distribution in the range from 85% to 115% with 97% probability and a value 84% with 3% probability

  20. EU Option 2 and PTIT_matchUSP90for 2 special cases

  21. Conclusion • A large difference in acceptance probability between EU option 1 and PTIT_matchUSP90 when the batch mean is off-target. • Larger passing probability for EU Option 1 than PTIT_matchUSP90 • No much difference in acceptance probability between EU option 1 and PTIT_matchUSP90 when the batch mean is on-target. • Bias of EU Option 1 • EU Option 1 has higher probability of passing the off-target product than that of passing the on-target mean product for a given coverage within (85%, 115%)

  22. Conclusion (continued) • EU Option 2 • Issue with a large variability for a mixture of 97% probability of distributing uniformly with (85%, 115%) and 3% probability of being 84%) using a sample of 200 • 60% probability to pass EU Option 2 • 0% probability to pass PTIT_matchUSP90 • 3% probability to pass USP harmonized • Issue with a location shift of the mean product • The same probability to pass the EU Option 2 for 97% population with 100% content and 97% population with 90% content. • Off target product: 97% population with 90% content using a sample of 150. • >50% probability to pass the EU Option 2 • About 1% probability to pass PTIT_matchUSP90

  23. References • USP Pharmacopoeia 2015 • European Pharmacopoeia 7.7 • European Pharmacopoeia 8.1 • Meiyu Shen, Yi Tsong, Xiaoyu Dong, Statistical Properties of Large Sample Tests for Dose Content Uniformity, Therapeutic Innovation & Regulatory Science, 2014, Vol. 48(5) 613-622 • Meiyu Shen and Yi Tsong, Bias Of The United States Pharmacopeia Harmonized Test For Dose Content Uniformity, United States Pharmacopeia forum, January 2011

  24. Thank you!

More Related